New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
C4BPA could prove useful as a diagnostic biomarker for early stage pancreatic cancer and to help differentiate the disease from other cancers.
The test could provide an early diagnosis of breast cancer by examining a handful of miRNA, microRNA, and proteomic biomarkers from urine samples.
ViveBio plans to develop an assay based on inflammatory protein and mRNA biomarkers for laboratory-developed and companion diagnostic testing.
NEW YORK (GenomeWeb) – BHC Center of Financial and Investment Business today announced it has invested in 20/20 GeneSystems to help bring the company's diagnostic test for lung cancer to China.
NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.
NEW YORK (GenomeWeb News) – Provista Diagnostics said today that it has licensed biomarker technologies developed by researchers at Arizona State University's Biodesign Institute.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.